ESMO Conference

The treatment of advanced renal clear cell carcinoma (ccRCC) has evolved from the cytokine era to the era of targeted therapy, immunotherapy, and immunotherapy combinations, expanding survival options for patients. However, results from the CONTACT-03 study suggest that continuing with immunotherapy combinations after immunotherapy failure may not be a preferred option, highlighting the need for exploration of subsequent treatment options for this patient population. Two significant studies presented at this year's ESMO conference (LBA87, LBA88) [2,3] indicate that, compared to everolimus, the HIF-2α inhibitor Belzutifan significantly improves the PFS and ORR of advanced ccRCC patients. Additionally, Belzutifan in combination with cabozantinib demonstrates persistent anti-tumor activity and safety consistent with previous observations. At the conference, "Oncology Frontier" had the privilege of inviting Professor Xinan Sheng from Peking University Cancer Hospital to provide in-depth insights.